PHARMING GROUP NV (PHARM.AS) Stock Overview
AMS:PHARM - NL0010391025 - Common Stock
PHARM.AS Key Statistics, Chart & Performance
The current stock price of PHARM.AS is 1.147 EUR. In the past month the price increased by 26.36%. In the past year, price increased by 50.24%.
PHARM.AS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 19.98 | 321.13B | ||
| AMG.DE | AMGEN INC | 13.74 | 138.41B | ||
| GIS.DE | GILEAD SCIENCES INC | 15.11 | 124.65B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 23.62 | 88.26B | ||
| ARGX.BR | ARGENX SE | 77.49 | 35.19B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 23.05B | ||
| IDP.DE | BIOGEN INC | 8.73 | 17.60B | ||
| 1MRNA.MI | MODERNA INC | N/A | 8.98B | ||
| 0QF.DE | MODERNA INC | N/A | 8.80B | ||
| ABVX.PA | ABIVAX SA | N/A | 4.89B | ||
| 1VKTX.MI | VIKING THERAPEUTICS INC | N/A | 2.47B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.82B |
Related stock screener links
About PHARM.AS
Company Profile
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 426 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Company Info
PHARMING GROUP NV
Darwinweg 24
Leiden ZUID-HOLLAND NL
Employees: 404
Phone: 31715247400
PHARMING GROUP NV / PHARM.AS FAQ
What is the stock price of PHARMING GROUP NV today?
The current stock price of PHARM.AS is 1.147 EUR. The price increased by 4.94% in the last trading session.
What is the ticker symbol for PHARMING GROUP NV stock?
The exchange symbol of PHARMING GROUP NV is PHARM and it is listed on the Euronext Amsterdam exchange.
On which exchange is PHARM.AS stock listed?
PHARM.AS stock is listed on the Euronext Amsterdam exchange.
What is the price forecast or stock price prediction for PHARMING GROUP NV stock?
14 analysts have analysed PHARM.AS and the average price target is 6.24 EUR. This implies a price increase of 444.07% is expected in the next year compared to the current price of 1.147. Check the PHARMING GROUP NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PHARMING GROUP NV worth?
PHARMING GROUP NV (PHARM.AS) has a market capitalization of 78.45M EUR. This makes PHARM.AS a Micro Cap stock.
How many employees does PHARMING GROUP NV have?
PHARMING GROUP NV (PHARM.AS) currently has 404 employees.
What are the support and resistance levels for PHARMING GROUP NV (PHARM.AS) stock?
PHARMING GROUP NV (PHARM.AS) has a support level at 0.99. Check the full technical report for a detailed analysis of PHARM.AS support and resistance levels.
Is PHARMING GROUP NV (PHARM.AS) expected to grow?
The Revenue of PHARMING GROUP NV (PHARM.AS) is expected to grow by 13.88% in the next year. Check the estimates tab for more information on the PHARM.AS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PHARMING GROUP NV (PHARM.AS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PHARM.AS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PHARM.AS, evaluating the profitability, health, valuation and growth aspects
- PHARMING GROUP NV (PHARM.AS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PHARMING GROUP NV (PHARM.AS) Sales and EPS estimates to see what analysts future expectations are.
- PHARMING GROUP NV (PHARM.AS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PHARMING GROUP NV (PHARM.AS) Insider and Institutional Ownership to learn about the owners and their transactions.
- PHARMING GROUP NV (PHARM.AS) Stock Chart to make your own analysis
- PHARMING GROUP NV (PHARM.AS) Latest news and press-releases to stay up to date.
Does PHARMING GROUP NV (PHARM.AS) stock pay dividends?
PHARM.AS does not pay a dividend.
When does PHARMING GROUP NV (PHARM.AS) report earnings?
PHARMING GROUP NV (PHARM.AS) will report earnings on 2025-11-06.
What is the Price/Earnings (PE) ratio of PHARMING GROUP NV (PHARM.AS)?
PHARMING GROUP NV (PHARM.AS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.01).
PHARM.AS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PHARM.AS. When comparing the yearly performance of all stocks, PHARM.AS is one of the better performing stocks in the market, outperforming 91.69% of all stocks.
PHARM.AS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PHARM.AS. PHARM.AS has an average financial health and profitability rating.
PHARM.AS Financial Highlights
Over the last trailing twelve months PHARM.AS reported a non-GAAP Earnings per Share(EPS) of -0.01. The EPS increased by 50% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.84% | ||
| ROE | -3.42% | ||
| Debt/Equity | 0.5 |
PHARM.AS Forecast & Estimates
14 analysts have analysed PHARM.AS and the average price target is 6.24 EUR. This implies a price increase of 444.07% is expected in the next year compared to the current price of 1.147.
For the next year, analysts expect an EPS growth of 183.09% and a revenue growth 13.88% for PHARM.AS